Study Summary
This is a single-arm, open-label, exploratory clinical study to evaluate the safety, tolerability and preliminary efficacy of Anti-Mesothelin CAR-T cell injection in patients with Mesothelin-positive advanced malignant solid tumors.
Want to learn more about this trial?
Request More InfoInterventions
Anti-mesothelin CAR-T cellsBIOLOGICAL
D0: 0.1×10\^6/Kg\~1.0×10\^6/Kg; cells will be infused intravenously.
FludarabineDRUG
D-7 to D-3: Fludarabine (25 mg/m\^2/day) will be administered intravenously for 5 days.
CyclophosphamideDRUG
D-7 to D-3: Cyclophosphamide (300 mg/m\^2/day) will be administered intravenously for 5 days.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| The First Affiliated Hospital Zhejiang University School of Medicine | Hangzhou | China |